Impact of ETIF deletion on safety and immunogenicity of equine herpesvirus type 1-vectored vaccines.
Heterologous gene transfer by viral vector systems is often limited by factors such as preexisting immunity, toxicity, low packaging capacity, or weak immunogenic potential. A novel viral vector system derived from equine herpesvirus type 1 (EHV-1) not only overcomes some of these obstacles but also promotes the robust expression of a delivered transgene and the induction of antigen-specific immune responses. Regarding an enhanced safety profile, we assessed the impact of the gene encoding the sole essential tegument protein, ETIF, on the replication and immunogenicity of recombinant EHVs. The deletion of ETIF severely attenuates replication in permissive RK13 cells and a human lung epithelial cell line but without influencing transgene expression. Whereas the intranasal administration of a recombinant luciferase EHV in BALB/c mice resulted in transgene expression in nasal cavities and lungs for 5 to 6 days, the ETIF deletion limited expression to 2 days and resulted in 30-fold-less luminescence. Attenuated replication was accompanied by a decreased capacity to induce CD8(+) T cells against a delivered HIV Gag transgene in BALB/c mice following repeated intranasal application. However, a single subcutaneous immunization with a gag DNA vaccine primed specific T cells for substantial expansion by two subsequent intranasal booster immunizations with either the gag recombinant ETIF mutant or the parental virus. In addition to inducing Gag-specific serum antibodies, this prime-boost strategy clearly outperformed three sequential immunizations with the parental or EHV-ΔETIF virus or repeated DNA vaccination by inducing substantial specific secretory IgA (sIgA) titers.
Hofmann-Sieber
Helga
H
Institute of Medical Microbiology, University of Regensburg, Regensburg, Germany.
Wild
Jens
J
Fiedler
Nicole
N
Tischer
Karsten
K
von Einem
Jens
J
Osterrieder
Nikolaus
N
Hofmann
Heike
H
Köstler
Josef
J
Wagner
Ralf
R
D000818:Animals; D002460:Cell Line; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D017353:Gene Deletion; D005822:Genetic Vectors / Q000009:adverse effects* / Q000235:genetics / Q000276:immunology*; D004861:Herpesvirus 1, Equid / Q000235:genetics* / Q000276:immunology / Q000502:physiology; D006801:Humans; D007114:Immunization; D051379:Mice; D008807:Mice, Inbred BALB C; D014612:Vaccines / Q000235:genetics / Q000276:immunology*; D015678:Viral Structural Proteins / Q000235:genetics* / Q000276:immunology; D014779:Virus Replication
D014612:Vaccines; D015678:Viral Structural Proteins
AIDS. 1999 Jan 14;13(1):23-9
10207541
Vaccine. 2005 Jan 11;23(8):1029-36
15620476
Biotechniques. 2006 Feb;40(2):191-7
16526409
Immunol Lett. 2001 Nov 1;79(1-2):29-36
11595287
Methods Mol Biol. 2004;246:257-99
14970599
Virology. 1996 Dec 15;226(2):243-51
8955044
J Virol. 2005 Dec;79(24):15043-53
16306575
AIDS Res Hum Retroviruses. 2004 Sep;20(9):989-1004
15585086
J Virol. 2005 Jan;79(2):771-9
15613305
J Virol. 2000 Aug;74(15):6964-74
10888635
Nat Rev Immunol. 2002 Apr;2(4):239-50
12001995
Curr Opin Mol Ther. 2001 Oct;3(5):503-8
11699896
Mol Pharm. 2007 Jan-Feb;4(1):18-32
17274663
J Immunol. 1998 Nov 1;161(9):4463-6
9794366
Tuberculosis (Edinb). 2007 Aug;87 Suppl 1:S35-44
17652028
Virology. 1997 Apr 14;230(2):369-75
9143293
J Virol. 2005 May;79(9):5445-54
15827159
J Vet Med B Infect Dis Vet Public Health. 2002 Feb;49(1):31-6
11911590
Science. 2001 Apr 6;292(5514):69-74
11393868
Curr Opin Immunol. 2002 Oct;14(5):666-72
12183170
Methods Mol Med. 2004;94:197-210
14959831
J Virol. 2006 Mar;80(6):2609-20
16501071
J Virol. 2008 Jan;82(1):207-19
17942549
Clin Infect Dis. 2006 Aug 15;43(4):500-11
16838241
J Gen Virol. 1992 Feb;73 ( Pt 2):261-8
1347078
Vaccine. 2007 Dec 17;25(52):8874-84
18061316
Virology. 2007 Mar 30;360(1):36-49
17098273
FEMS Immunol Med Microbiol. 2002 Feb 18;32(3):179-85
11934561
J Virol. 2001 Nov;75(22):10991-1001
11602739
Mol Med Today. 1995 Dec;1(9):410-7
9415189
Genomics. 2001 Apr 1;73(1):56-65
11352566
Virus Res. 1987 Sep;8(3):233-44
2825444
Equine Vet J. 2001 Nov;33(7):651-7
11770985
J Virol. 2005 Aug;79(15):9933-44
16014954
J Mol Biol. 1983 Jun 5;166(4):557-80
6345791
Virology. 1994 Jan;198(1):385-9
8259676
DNA Cell Biol. 2002 Dec;21(12):915-36
12573050
J Exp Med. 2008 Jan 21;205(1):63-77
18195071
Trends Immunol. 2004 Feb;25(2):98-104
15102369
Vaccine. 2005 Mar 31;23(19):2454-64
15752831
Nature. 2007 Nov 15;450(7168):325
18004331
Zentralbl Veterinarmed B. 1968 Apr;15(3):406-18
5692868
Intervirology. 2002;45(4-6):275-86
12566710
Virology. 1993 Dec;197(2):788-92
8249301
J Virol. 2003 May;77(10):5589-97
12719551
Vaccine. 2007 Mar 30;25(14):2620-9
17280743
Virology. 2004 Aug 1;325(2):192-9
15246259
Infect Immun. 1997 Jul;65(7):2676-84
9199436
J Virol. 2004 Jan;78(1):146-57
14671096
Curr Opin Biotechnol. 2007 Dec;18(6):546-56
18063357
Curr Top Microbiol Immunol. 2006;304:153-63
16989269